Immix Biopharma Statistics
Total Valuation
Immix Biopharma has a market cap or net worth of $699.80 million. The enterprise value is $610.26 million.
| Market Cap | 699.80M |
| Enterprise Value | 610.26M |
Important Dates
The next estimated earnings date is Friday, August 7, 2026, after market close.
| Earnings Date | Aug 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Immix Biopharma has 71.19 million shares outstanding. The number of shares has increased by 31.93% in one year.
| Current Share Class | 71.19M |
| Shares Outstanding | 71.19M |
| Shares Change (YoY) | +31.93% |
| Shares Change (QoQ) | +37.65% |
| Owned by Insiders (%) | 9.55% |
| Owned by Institutions (%) | 41.21% |
| Float | 56.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.18 |
| P/TBV Ratio | 8.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.76, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.76 |
| Quick Ratio | 8.59 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -74.47% and return on invested capital (ROIC) is -46.95%.
| Return on Equity (ROE) | -74.47% |
| Return on Assets (ROA) | -38.97% |
| Return on Invested Capital (ROIC) | -46.95% |
| Return on Capital Employed (ROCE) | -42.31% |
| Weighted Average Cost of Capital (WACC) | 4.82% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.67M |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Immix Biopharma has paid $27,902 in taxes.
| Income Tax | 27,902 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +374.88% in the last 52 weeks. The beta is 0.11, so Immix Biopharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.11 |
| 52-Week Price Change | +374.88% |
| 50-Day Moving Average | 9.24 |
| 200-Day Moving Average | 6.61 |
| Relative Strength Index (RSI) | 56.42 |
| Average Volume (20 Days) | 2,097,510 |
Short Selling Information
The latest short interest is 3.97 million, so 5.57% of the outstanding shares have been sold short.
| Short Interest | 3.97M |
| Short Previous Month | 4.03M |
| Short % of Shares Out | 5.57% |
| Short % of Float | 6.99% |
| Short Ratio (days to cover) | 2.62 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -36.08M |
| Pretax Income | -34.95M |
| Net Income | -34.98M |
| EBITDA | -35.78M |
| EBIT | -36.08M |
| Earnings Per Share (EPS) | -$0.89 |
Balance Sheet
The company has $90.58 million in cash and $1.04 million in debt, with a net cash position of $89.54 million or $1.26 per share.
| Cash & Cash Equivalents | 90.58M |
| Total Debt | 1.04M |
| Net Cash | 89.54M |
| Net Cash Per Share | $1.26 |
| Equity (Book Value) | 84.36M |
| Book Value Per Share | 1.59 |
| Working Capital | 81.74M |
Cash Flow
In the last 12 months, operating cash flow was -$32.07 million and capital expenditures -$697,698, giving a free cash flow of -$32.77 million.
| Operating Cash Flow | -32.07M |
| Capital Expenditures | -697,698 |
| Depreciation & Amortization | 299,171 |
| Net Borrowing | n/a |
| Free Cash Flow | -32.77M |
| FCF Per Share | -$0.46 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immix Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -31.93% |
| Shareholder Yield | -31.93% |
| Earnings Yield | -5.00% |
| FCF Yield | -4.68% |
Analyst Forecast
The average price target for Immix Biopharma is $19.75, which is 100.92% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.75 |
| Price Target Difference | 100.92% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |